← Eichor
Study identifier: NCT06428422 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

The Impact of Probiotic on Survival and Treatment Response in Metastatic Non-small Cell Lung Cancer Patients

Condition: Metastatic Non-small Cell Lung Cancer  ·  Sponsor: Necmettin Erbakan University

PhaseNA
Planned participants100
Who can joinAll sexes, 19 Years to 90 Years
Healthy volunteersNo

About this study

The aim of this study is to evaluate the effect of a probiotic supplement containing Bifidobacterium animalis lactis BL-04 on the clinical effectiveness of immunotherapy in patients diagnosed with metastatic non-small cell lung cancer who are receiving immunotherapy.

This description comes directly from the study's public registry record.

Talk to the study team

Mehmet Artaç, MD  ·  +90332236000  ·  martac@erbakan.edu.tr

Always discuss trial participation with your own doctor first.

Locations (1)

Necmettin Erbakan UniversityKonya, Turkey (Türkiye)Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06428422